Polymyositis (PM) and
dermatomyositis (DM) are the two subtypes of
idiopathic inflammatory myositis and are characterized as symmetrical progressive
muscle weakness in the proximal extremities. PM/DM affect multiple organs and systems, including the cardiovascular, respiratory and digestive tract systems. An in-depth understanding of PM/DM
biomarkers will facilitate development of simple and accurate strategies for diagnosis, treatment, and prognosis prediction. This review summarized the classic
biomarkers of PM/DM, including anti-aminoacyl
tRNA synthetases (ARS) antibody,
anti-Mi-2 antibody, anti-
melanoma differentiation-associated gene 5 (MDA5) antibody, anti-transcription intermediary factor 1-γ (TIF1-γ) antibody, anti-
nuclear matrix protein 2 (NXP2) antibody, among others. Among them, anti-aminoacyl
tRNA synthetases antibody is the most classic. In addition, many potential novel
biomarkers were also discussed in this review, including anti-HSC70 antibody, YKL-40,
interferons, myxovirus resistance
protein 2,
regenerating islet-derived protein 3-α,
interleukin (IL)-17, IL-35,
microRNA (miR)-1 and so on. Among the
biomarkers of PM/DM described in this review, classic
biomarkers have become the mainstream
biomarkers to assist clinicians in diagnosis due to their early discovery, in-depth research, and widespread application. The novel
biomarkers also have potential and broad research prospects, which will make immeasurable contributions to exploring
biomarker-based classification standards and expanding their application value.